ATE497540T1 - Transposon-system zur gezielten integration - Google Patents

Transposon-system zur gezielten integration

Info

Publication number
ATE497540T1
ATE497540T1 AT04709591T AT04709591T ATE497540T1 AT E497540 T1 ATE497540 T1 AT E497540T1 AT 04709591 T AT04709591 T AT 04709591T AT 04709591 T AT04709591 T AT 04709591T AT E497540 T1 ATE497540 T1 AT E497540T1
Authority
AT
Austria
Prior art keywords
transposase
fragment
derivative
function
domain
Prior art date
Application number
AT04709591T
Other languages
English (en)
Inventor
Zoltan Ivics
Zsuzsanna Izsvak
Original Assignee
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum filed Critical Max Delbrueck Centrum
Application granted granted Critical
Publication of ATE497540T1 publication Critical patent/ATE497540T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04709591T 2003-02-10 2004-02-10 Transposon-system zur gezielten integration ATE497540T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002630 2003-02-10
PCT/EP2004/001222 WO2004069995A2 (en) 2003-02-10 2004-02-10 Transposon-based targeting system

Publications (1)

Publication Number Publication Date
ATE497540T1 true ATE497540T1 (de) 2011-02-15

Family

ID=32842693

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709591T ATE497540T1 (de) 2003-02-10 2004-02-10 Transposon-system zur gezielten integration

Country Status (7)

Country Link
US (1) US20060236413A1 (de)
EP (1) EP1594971B1 (de)
JP (1) JP2006517104A (de)
AT (1) ATE497540T1 (de)
DE (1) DE602004031284D1 (de)
DK (1) DK1594971T3 (de)
WO (1) WO2004069995A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040172667A1 (en) 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
ATE536419T1 (de) * 2003-02-10 2011-12-15 Max Delbrueck Centrum Transposon basiertes targeting- system
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
EP2067402A1 (de) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transposon-vermittelte Mutagenese in Spermatogoniestammzellen
US9157097B2 (en) 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone
WO2010036976A2 (en) 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
US8735156B2 (en) 2008-12-01 2014-05-27 The Board Of Regents Of The University Of Texas System Production and use of rat spermatogonial stem cell lines
EP2417263B1 (de) 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Herstellung von proteinen unter verwendung von vektoren auf transposonbasis
US9074251B2 (en) 2011-02-10 2015-07-07 Illumina, Inc. Linking sequence reads using paired code tags
AU2012212148B8 (en) 2011-02-02 2017-07-06 University Of Washington Through Its Center For Commercialization Massively parallel contiguity mapping
EP2740353A1 (de) 2012-12-06 2014-06-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige induzierbare Tiermodelle für Stressverhalten
US9683230B2 (en) 2013-01-09 2017-06-20 Illumina Cambridge Limited Sample preparation on a solid support
US10557133B2 (en) 2013-03-13 2020-02-11 Illumina, Inc. Methods and compositions for nucleic acid sequencing
WO2014143383A1 (en) * 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
CN106414765A (zh) 2013-12-20 2017-02-15 Illumina公司 在片段化的基因组dna样品中保留基因组连接信息
FR3024464A1 (fr) * 2014-07-30 2016-02-05 Centre Nat Rech Scient Ciblage de vecteurs integratifs non-viraux dans les sequences d'adn nucleolaires chez les eucaryotes
WO2016061517A2 (en) 2014-10-17 2016-04-21 Illumina Cambridge Limited Contiguity preserving transposition
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7097494A (en) * 1993-06-01 1994-12-20 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
KR0166606B1 (ko) * 1993-12-07 1999-04-15 가네코 야스조 배선용 바닥 재료
KR20000076157A (ko) * 1997-03-11 2000-12-26 리전츠 오브 더 유니버스티 오브 미네소타 세포의 디엔에이로 핵산을 도입하는 디엔에이-기초 전이인자 시스템
WO1999005295A1 (en) * 1997-07-25 1999-02-04 Thomas Jefferson University Composition and method for targeted integration into cells
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
US20040091878A1 (en) * 2000-07-21 2004-05-13 Takashi Sera Zinc finger domain recognition code and uses thereof
CA2533708C (en) * 2002-07-24 2013-05-14 Vanderbilt University Transposon-based vectors and methods of nucleic acid integration

Also Published As

Publication number Publication date
WO2004069995A2 (en) 2004-08-19
US20060236413A1 (en) 2006-10-19
DK1594971T3 (da) 2011-05-23
EP1594971A2 (de) 2005-11-16
WO2004069995A3 (en) 2004-10-28
EP1594971B1 (de) 2011-02-02
DE602004031284D1 (de) 2011-03-17
JP2006517104A (ja) 2006-07-20

Similar Documents

Publication Publication Date Title
ATE536419T1 (de) Transposon basiertes targeting- system
ATE497540T1 (de) Transposon-system zur gezielten integration
WO2007031280A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2005005462A3 (en) Blys antagonists and uses thereof
ATE498016T1 (de) Transposon-system zur gezielten integration
WO2003102132A3 (en) Non-affinity purification of proteins
SG162687A1 (en) Caustic stable chromatography ligands
WO2007046006A3 (en) Il-15ralpha sushi domain as a selective and potent enhancer of il-15 action through il-15rbeta/gamma, and hyperagonist (ilralpha sushi-il 15) fusion proteins
MX2009005901A (es) Nuevos polipeptidos cristalinos de bacillus thuringiensis, polinucleotidos y composiciones de los mismos.
ATE466868T1 (de) Zusammensetzungen und verfahren zur trennung von fusionsproteinen
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
WO2007140505A3 (en) Vaccine carrier
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE60212804D1 (de) Sicherheitssystem
EA200800570A1 (ru) Фосфонированные рифамицины и их применение для профилактики и лечения костных и суставных инфекций
TW200716132A (en) Novel chemical compounds
WO2004090103A3 (en) Identification of novel nogo-receptors and methods related thereto
ATE521626T1 (de) Fusionsprotein zur inhibierung von gebärmutterhalskrebs
WO2006097336A3 (en) A novel component of the wg/wnt signaling pathway
IL157309A0 (en) Method for the purification of a non-immunoglobulin protein
WO2006127458A3 (en) Novel chemical compounds
ATE328904T1 (de) Modulation der tetraspanin funktion
WO2007044031A3 (en) Methods and compositions for detecting bacillus anthracis
WO2001070980A3 (en) Isolated g-protein coupled receptors, nucleic acid molecules encoding gpcr proteins, and uses thereof as insecticidal targets
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties